Lumenis gets antitrust case and questions from SEC (US Securities and Exchange Commission)
This article was originally published in Clinica
Executive Summary
Laser company Lumenis has had an antitrust and patent infringement claim slapped on it just days after receiving a request from the US Securities and Exchange Commission (SEC) for documents and information. Shares in the company fell by over 30% to around $9, although the company also had some good news in the form of an agreement to refinance a $100 million term loan and $71 million in convertible bonds.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.